Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Hepatitis C virus therapy update 2013.

Casey LC, Lee WM.

Curr Opin Gastroenterol. 2013 May;29(3):243-9. doi: 10.1097/MOG.0b013e32835ff972. Review.

PMID:
23563981
2.

Future of hepatitis C therapy: development of direct-acting antivirals.

Dore GJ, Matthews GV, Rockstroh J.

Curr Opin HIV AIDS. 2011 Nov;6(6):508-13. doi: 10.1097/COH.0b013e32834b87f8. Review.

PMID:
21897228
3.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
4.

Direct-acting antiviral (DAA) actions in treatment-naïve patients.

Hézode C.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S52-8. doi: 10.1016/S2210-7401(11)70008-0.

PMID:
22248695
5.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
6.

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].

Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli Association for the Study of the Liver.

Harefuah. 2012 Dec;151(12):709-14, 719. Hebrew.

PMID:
23330266
7.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

8.

Hepatitis C therapy update.

Casey LC, Lee WM.

Curr Opin Gastroenterol. 2012 May;28(3):188-92. doi: 10.1097/MOG.0b013e3283528e1e. Review.

PMID:
22476156
9.

Treatment failure with new hepatitis C drugs.

Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P.

Expert Opin Pharmacother. 2012 Feb;13(3):313-23. doi: 10.1517/14656566.2012.653341. Epub 2012 Jan 14. Review.

PMID:
22242928
10.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Sitole M, Silva M, Spooner L, Comee MK, Malloy M.

Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.

PMID:
23369368
11.

Future perspectives: towards interferon-free regimens for HCV.

Gane E.

Antivir Ther. 2012;17(6 Pt B):1201-10. doi: 10.3851/IMP2431. Epub 2012 Oct 5. Review.

PMID:
23186654
12.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
13.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

14.

The role of resistance in HCV treatment.

Vermehren J, Sarrazin C.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011. Review.

PMID:
23199507
15.

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.

Welsch C, Jesudian A, Zeuzem S, Jacobson I.

Gut. 2012 May;61 Suppl 1:i36-46. doi: 10.1136/gutjnl-2012-302144. Review. Erratum in: Gut. 2012 Aug;61(8):1145.

PMID:
22504918
16.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
17.

Rapid progression of antiviral treatments of chronic hepatitis C virus infection.

Pol S, Corouge M, Mallet V, Sogni P.

Minerva Gastroenterol Dietol. 2013 Jun;59(2):161-72.

PMID:
23831907
18.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

19.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
20.

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).

Sheridan DA, Neely RD, Bassendine MF.

Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):10-6. doi: 10.1016/j.clinre.2012.07.002. Epub 2012 Sep 5. Review.

PMID:
22959093
Items per page

Supplemental Content

Write to the Help Desk